Expert Ratings For NeoGenomics
Portfolio Pulse from Benzinga Insights
NeoGenomics (NASDAQ:NEO) has received recent analyst ratings, with 3 analysts being bullish and 1 somewhat bullish. The average 12-month price target is $18.5. Despite revenue growth, NeoGenomics faces challenges with profitability and returns, as indicated by its net margin, ROE, and ROA being below industry averages.
September 24, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NeoGenomics has received positive analyst ratings, with 3 analysts bullish and 1 somewhat bullish. The average price target is $18.5, indicating stable expectations. However, the company faces challenges in profitability and returns, with net margin, ROE, and ROA below industry averages.
The positive analyst ratings and stable price target suggest a favorable short-term outlook for NeoGenomics. However, the company's financial metrics indicate challenges in profitability and returns, which could temper investor enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100